Latest News and Press Releases

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of...

ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug...

New York, USA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Pruritus Pipeline Analysis Demonstrates 27+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight ...

ROCKVILLE, Md., June 21, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today launched a new education and awareness campaign that will raise awareness of pruritus and help people with...

ROCKVILLE, Md., March 31, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced sponsorship from Vifor Pharma for an education and awareness campaign on chronic kidney...

Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of COVID-19 Restrictions Announces $14 Million Term Loan - Cash...

-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....

-- SNA-120, a new chemical entity derived from the company’s Topical by Design™ platform, was well tolerated with minimal to no detectable systemic exposure -- Vast majority of psoriasis patients...

WESTLAKE VILLAGE, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that pre-clinical data from the Company’s topical product candidate SNA-125,...

WESTLAKE VILLAGE, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the formation of a Corporate Advisory Board that will provide scientific,...